Cryo-Cell International (NYSEAMERICAN:CCEL) Share Price Passes Above 50 Day Moving Average – Time to Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) shares passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.57 and traded as high as $3.79. Cryo-Cell International shares last traded at $3.79, with a volume of 659 shares traded.

Cryo-Cell International Trading Down 6.4%

The firm’s 50-day moving average is $3.57 and its 200-day moving average is $3.49. The firm has a market cap of $30.55 million, a price-to-earnings ratio of -11.48 and a beta of 0.48.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its quarterly earnings data on Tuesday, April 14th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $7.68 million for the quarter.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International as of its most recent filing with the Securities and Exchange Commission. 10.44% of the stock is currently owned by institutional investors and hedge funds.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.